Neurogene Inc. Earnings Per Share (Diluted)
Neurogene Inc. (NGNE) reported Earnings Per Share (Diluted) of -$1.53 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-11
- Neurogene Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$1.53.
- Neurogene Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$1.39.
- Neurogene Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$1.12.
- Neurogene Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.99.
- Neurogene Inc. earnings per share, diluted for fiscal 2025 was -$4.24.
- Neurogene Inc. earnings per share, diluted for fiscal 2024 was -$4.28.
- Neurogene Inc. earnings per share, diluted for fiscal 2022 was -$1.04.
- Neurogene Inc. earnings per share, diluted for fiscal 2021 was -$1.10.
| Period end | Earnings Per Share, Diluted 0 month | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 123 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.53 10-Q · filed 2026-08-11 | -$2.92 10-Q · filed 2026-08-11 | -$4.04 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$5.04 derived: net income ÷ weighted average shares · filed 2026-08-11 | |||||
| 2026-03-31 | -$1.39 10-Q · filed 2026-05-12 | -$2.51 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.51 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$4.56 derived: net income ÷ weighted average shares · filed 2026-08-11 | |||||
| 2025-12-31 | -$1.12 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$2.11 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$3.16 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$4.24 10-K · filed 2026-03-24 | |||||
| 2025-09-30 | -$0.99 10-Q · filed 2025-11-13 | -$2.04 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.11 10-Q · filed 2025-11-13 | -$4.12 derived: net income ÷ weighted average shares · filed 2026-08-11 | |||||
| 2025-06-30 | -$1.05 10-Q · filed 2026-08-11 | -$2.12 10-Q · filed 2026-08-11 | -$3.13 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$4.30 derived: net income ÷ weighted average shares · filed 2026-08-11 | |||||
| 2025-03-31 | -$1.08 10-Q · filed 2026-05-12 | -$2.08 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.26 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$4.35 derived: net income ÷ weighted average shares · filed 2026-08-11 | |||||
| 2024-12-31 | -$1.00 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$2.18 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$3.27 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$4.28 10-K · filed 2026-03-24 | |||||
| 2024-09-30 | -$1.19 10-Q · filed 2025-11-13 | -$2.28 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$3.29 10-Q · filed 2025-11-13 | ||||||
| 2024-06-30 | -$1.09 10-Q · filed 2025-08-11 | -$2.09 10-Q · filed 2025-08-11 | |||||||
| 2024-03-31 | -$1.00 10-Q · filed 2025-05-09 | ||||||||
| 2023-12-31 | $2.93 10-K · filed 2025-03-24 | ||||||||
| 2023-09-30 | -$32.67 10-Q · filed 2024-11-18 | -$0.41 10-Q · filed 2023-11-14 | -$59.36 derived: net income ÷ weighted average shares · filed 2024-11-18 | -$87.66 10-Q · filed 2024-11-18 | -$1.86 10-Q · filed 2023-11-14 | -$0.82 derived: net income ÷ weighted average shares · filed 2024-11-18 | |||
| 2023-06-30 | -$26.68 10-Q · filed 2024-08-09 | -$0.04 10-Q · filed 2023-08-10 | -$54.94 10-Q · filed 2024-08-09 | -$0.29 10-Q · filed 2023-08-10 | -$0.43 derived: net income ÷ weighted average shares · filed 2024-11-18 | -$0.76 derived: net income ÷ weighted average shares · filed 2024-11-18 | |||
| 2023-03-31 | -$0.26 10-Q · filed 2023-05-08 | -$0.19 derived: net income ÷ weighted average shares · filed 2024-11-18 | -$0.43 derived: net income ÷ weighted average shares · filed 2024-11-18 | -$0.67 derived: net income ÷ weighted average shares · filed 2024-11-18 | |||||
| 2022-12-31 | -$0.06 derived: net income ÷ weighted average shares · filed 2024-03-18 | -$0.24 derived: net income ÷ weighted average shares · filed 2024-03-18 | -$0.47 derived: net income ÷ weighted average shares · filed 2024-03-18 | -$1.04 10-K · filed 2023-03-20 | |||||
| 2022-09-30 | -$1.18 10-Q · filed 2023-11-14 | -$0.24 10-Q · filed 2022-11-14 | -$0.87 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$3.99 10-Q · filed 2023-11-14 | -$0.80 10-Q · filed 2022-11-14 | -$1.34 derived: net income ÷ weighted average shares · filed 2023-11-14 | |||
| 2022-06-30 | -$0.28 10-Q · filed 2023-08-10 | -$0.56 10-Q · filed 2023-08-10 | -$0.84 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$1.12 derived: net income ÷ weighted average shares · filed 2023-11-14 | |||||
| 2022-03-31 | -$0.28 10-Q · filed 2023-05-08 | -$0.55 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$0.83 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$1.11 derived: net income ÷ weighted average shares · filed 2023-11-14 | |||||
| 2021-12-31 | -$0.28 derived: net income ÷ weighted average shares · filed 2023-03-20 | -$0.56 derived: net income ÷ weighted average shares · filed 2023-03-20 | -$0.83 derived: net income ÷ weighted average shares · filed 2023-03-20 | -$1.10 10-K · filed 2023-03-20 | |||||
| 2021-09-30 | -$0.28 10-Q · filed 2022-11-14 | -$0.56 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$0.83 10-Q · filed 2022-11-14 | -$1.06 derived: net income ÷ weighted average shares · filed 2022-11-14 | |||||
| 2021-06-30 | -$0.27 10-Q · filed 2022-08-09 | -$0.55 10-Q · filed 2022-08-09 | -$0.78 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$0.82 derived: net income ÷ weighted average shares · filed 2022-11-14 | |||||
| 2021-03-31 | -$0.27 10-Q · filed 2022-05-09 | -$0.50 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$0.55 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$0.74 derived: net income ÷ weighted average shares · filed 2022-11-14 | |||||
| 2020-12-31 | -$0.23 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$0.27 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$0.47 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$0.64 10-K · filed 2022-03-01 | |||||
| 2020-09-30 | -$0.04 10-Q · filed 2021-11-04 | -$0.23 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$0.41 10-Q · filed 2021-11-04 | ||||||
| 2020-06-30 | -$0.20 10-Q · filed 2021-08-05 | -$0.37 10-Q · filed 2021-08-05 | |||||||
| 2020-03-31 | -$0.18 10-Q · filed 2021-05-12 | ||||||||
| 2019-06-30 | -$0.00 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$0.09 10-Q · filed 2019-08-01 | |||||||
| 2018-06-30 | $0.12 10-Q · filed 2019-08-01 | -$0.50 10-Q · filed 2019-08-01 | |||||||
| 2017-06-30 | -$0.59 10-Q · filed 2018-08-08 | -$0.94 10-Q · filed 2018-08-08 | |||||||
| 2014-03-31 | -$1.28 10-Q · filed 2014-05-13 | -$179.45 10-Q · filed 2014-05-13 | |||||||
| 2013-03-31 | -$8.48 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |